Erschienen in:
02.12.2023 | COMMENTARY
Stroke prevention in atrial fibrillation: not a “one size fits all” endeavor
verfasst von:
Graham Peigh, Rod S. Passman
Erschienen in:
Journal of Interventional Cardiac Electrophysiology
|
Ausgabe 3/2024
Einloggen, um Zugang zu erhalten
Excerpt
Despite recent advances in pharmacology and device technology, thromboembolic cerebrovascular accident (CVA) remains the most dreaded consequence of atrial fibrillation (AF). Prior research demonstrates that AF is associated with a fivefold increase in the risk of CVA, and that the disability secondary to AF-associated CVA is significantly greater than that attributed to non-AF-associated CVA [
1]. While direct oral anticoagulants (DOACs) are associated with a significant reduction in CVA among those with AF, this is balanced by an increased risk of major bleed—particularly in high-risk cohorts [
2]. For this reason, nearly 50% of patients with AF who are prescribed an OAC do not initiate or maintain use [
3]. …